Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

442
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
442
Retroviruses02:33

Retroviruses

15.6K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
15.6K
Subviral Agents01:29

Subviral Agents

717
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
717
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.5K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.5K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

2.1K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parasite defense covaries with reproductive timing, not with resistance.

bioRxiv : the preprint server for biology·2026
Same author

Neospora caninum Infection in Marine Mammals Stranding in Northeastern Pacific Ocean Region.

Emerging infectious diseases·2026
Same author

Boom-Bust Cycles Constrain Host-Parasite Dynamics, Suppress Parasite Spread, and Drive Parasites Extinct.

The American naturalist·2025
Same author

Host avoidance and resistance vary independently and are specific to parasite genotype.

The Journal of animal ecology·2025
Same author

Concomitant group A Streptococcus and disseminated mpox infection mimicking relapsed diffuse large B-cell lymphoma.

JAAD case reports·2025
Same author

Avoidance of infection.

Current biology : CB·2025

Related Experiment Video

Updated: Mar 17, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K

Tenofovir Alafenamide.

Amanda K Gibson1, Bhavik M Shah2, Puja H Nambiar3

  • 11 Northwestern Memorial Hospital, Chicago, IL, USA.

The Annals of Pharmacotherapy
|July 29, 2016
PubMed
Summary

Tenofovir alafenamide (TAF) offers HIV-1 treatment efficacy comparable to tenofovir disoproxil fumarate (TDF) but with improved safety. This novel nucleotide reverse transcriptase inhibitor shows reduced bone and kidney side effects, making it a valuable therapeutic option.

Keywords:
GS-7430TAFtenofovirtenofovir-alafenamide

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

3.0K

Related Experiment Videos

Last Updated: Mar 17, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

3.0K

Area of Science:

  • Pharmacology and Therapeutics
  • Infectious Diseases
  • Antiviral Drug Development

Background:

  • Tenofovir alafenamide (TAF) is a newer prodrug of tenofovir, designed to improve upon the safety profile of tenofovir disoproxil fumarate (TDF).
  • TAF achieves higher intracellular concentrations of tenofovir with lower serum levels compared to TDF.
  • This pharmacokinetic advantage is hypothesized to reduce systemic toxicity associated with tenofovir therapy.

Purpose of the Study:

  • To comprehensively review the pharmacology, clinical efficacy, safety profile, and therapeutic positioning of tenofovir alafenamide (TAF).
  • To evaluate TAF's role in the management of HIV-1 infection based on available scientific evidence.

Main Methods:

  • Literature search of PubMed (2004-2016) using keywords: tenofovir alafenamide, TAF, and GS-7340.
  • Inclusion of in vitro studies, Phase I-III clinical trials, and pharmacokinetic/pharmacodynamic evaluations.
  • Review of conference abstracts from major infectious diseases and HIV meetings.

Main Results:

  • Clinical trials confirm TAF's efficacy is similar to TDF in achieving virological suppression in HIV-1 patients.
  • TAF-containing regimens demonstrate significant improvements in kidney function markers and bone mineral density compared to TDF.
  • Three TAF-containing combination products are FDA-approved for HIV-1 management, with one recommended for initial therapy.

Conclusions:

  • Tenofovir alafenamide (TAF) is an effective nucleotide reverse transcriptase inhibitor for HIV-1 treatment.
  • TAF exhibits comparable efficacy to TDF but with a superior safety profile, particularly regarding nephrotoxicity and bone density.
  • TAF represents a significant advancement in HIV therapy, offering improved patient outcomes and tolerability.